{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-270328","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-06-15T12:15:16+00:00","discovered_at":"2026-06-15T12:20:00.342208+00:00","generated_at":"2026-06-15T12:20:33.726914+00:00","sec_items":["1.01","2.03","2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neumora discontinues navacaprant after Phase 3 MDD failures; cuts workforce 35%","bullets":["Navacaprant failed primary endpoint in KOASTAL-2 (p=0.813) and KOASTAL-3 (p=0.480); development discontinued.","Company reducing workforce ~35%, expects ~$10M annualized savings, ~$2M restructuring costs in Q2 2026.","Cash and cash equivalents expected to fund operations into Q3 2027.","Pipeline focus shifts to NMRA-511 (Alzheimer's agitation), NMRA-898 (schizophrenia), NMRA-215 (obesity) with multiple milestones in H2 2026.","Third Amendment to loan agreement extends interest-only period; minimum liquidity covenant tied to milestones or market cap effective July 1, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-270328","json":"https://secwatch.observer/filing/0001193125-26-270328.json","markdown":"https://secwatch.observer/filing/0001193125-26-270328.md","text":"https://secwatch.observer/filing/0001193125-26-270328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:20:33.726914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b557a4901b310d6ec1485f1d54bcd7eece120a47","claim":"Neumora Therapeutics, Inc. amended Third Amendment to the Loan and Security Agreement with K2 HealthVentures LLC (effective 2026-06-10).","evidence_excerpt":"On June 10, 2026, Neumora Therapeutics, Inc. (the “Company” or “Neumora”) as borrower, entered into a Third Amendment to the Loan and Security Agreement (the “Third Amendment”), with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for Lenders.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"K2 HealthVentures LLC"},{"label":"Effective","value":"2026-06-10"}],"fact_type":"material_agreement"},{"claim_id":"fe792909c738c761b0e7d686768c4c56481bbbff","claim":"Neumora Therapeutics, Inc. announced a restructuring with charges of approximately $2 million (approximately 35%).","evidence_excerpt":"On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately $2 million to be incurred in the second quarter of 2026.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/0001193125-26-270328-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2 million"},{"label":"Headcount","value":"approximately 35%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}